SBIR/STTR Research Award

Molecular Mammography of Her-2 Cancers using Gold Nanoparticles

Award identifier 978a592dbcd36b0e9e334ccf9153a5686ffa501967629c8d2a5b54d85a3fa24bAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$179,787

Program and phase

SBIR · Phase I

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NANOPROBES INC
Proposal award date
Not reported
Contract end date
Not reported
UEI
JK7BK6JL14M6
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Cancer imaging is important for tumor detection, determination of prognosis and treatments, image guided surgery and irradiation, as well as for monitoring responses. Molecular imaging of specific targets could identify tumor types and enable selection of appropriate drugs. Although x-ray imaging is widely used and more rapid with higher resolution compared to PET, SPECT, and MRI, there are currently no targeted x-ray contrast agents. In this proposal we will develop molecular targeted agents for mammography by a nanotechnology approach using gold nanoparticles for imaging cancers. The Her 2 protein on breast cancer cells will be targeted by use of antibodies attached to biocompatible gold nanoparticles using a mouse model. This would then be useful for non-invasive in vivo detection of this mutation which occurs in about 30% of human breast cancers that could then be beneficially treated with the monoclonal antibody Herceptin(r). Molecular mammography imaging would improve on the limited sampling afforded by painful biopsies and provide more thorough detection of even small tumors and metastases missed by biopsies and other methods. It would enable earlier detection of breast cancer. Better tumor definition would also improve precise radiotherapy, surgery, and follow-up monitoring. If successful, this technology could be applied to other tumors for early detection and biochemical typing for more effective individualized treatments. To Public Health: A novel method using nanotechnology will be developed for improved non-invasive imaging and detection of breast cancer types by mammography. This should not only enable better early detection of smaller tumors and metastases without painful biopsies, but identify tumor types so that specific drugs for the type can be administered. Such a need exists to detect Her2 breast cancers, which account for about 30% of breast cancers, where the specific drug Herceptin(r) is available and improves survival.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

47 SBIR/STTR records share this UEI (1991–2025). Reported award amounts total $12,102,185. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation, Department of Energy

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.